摘要 |
<p>The present invention relates to a radionuclide-labeled ethylenedicysteine (EC) derivative comprising a disease cell cycle targeting compound, wherein
(i) the EC forms an N2S2 chelate with the radionuclide,
(ii) the disease cell cycle targeting compound is a nucleoside, or analog thereof, and is selected from guanine, adenosine, penciclovir, FIAU, FIRU, FMAU, IVFRU, GCV, PCV, FGCV, FPCV, FHPG, and FHBG; and
(iii)the disease cell cycle targeting compound is conjugated to EC directly or via a linker.
</p> |
申请人 |
BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM;CELLPOINT LLC |
发明人 |
YANG, DAVID, J;YU, DONG-FANG;OH, CHANG-SOK;BRYANT, JERRY, L., JR |